Recently, the FDA expanded the indication of pembrolizumab to be included in frontline treatment of NSCLC patients with a PD-L1 expression level ≥1% that do not harbor ALK or EGFR mutations, who are unqualified for surgery or conclusive chemoradiation based on findings from the phase III KEYNOTE-042 trial [21]. Here, EGFR is linked to non-small cell lung carcinoma.